Ministring DNA (msDNA), is a novel gene delivery vector that paves the way for personalized, redoseable genetic medicine that is safe, effective and accessible. While competing vector technologies often compromise patient safety to ensure effectiveness, our technology is both safe and effective. With its unique linear covalently closed “string” topology, msDNA boasts a number of capabilities that allow it to outperform existing solutions and unlock the transition into true personalized genetic medicine.
Safer composition and design
Redoseable and titratable
Larger vector capacity
Scalable and efficient production
Site specific targeting
We are currently developing genetic medicines for inherited ocular diseases for which treatment options are limited or do not exist entirely.
Mediphage is actively seeking partners interested in evaluating msDNA through a joint feasibility study which can lead to the use of msDNA as part of a therapeutic solution. Specifically, within gene or cell therapy and gene editing categories, we are interested in T-cell and B-cell applications, DNA vaccines, iPSC, CRISPR and rAAV production.
If you are interested in partnering with us, we want to hear from you.
Construction and Characterization of an in-vivo Linear Covalently Closed DNA Vector Production System (2012)
DNA Ministrings: Highly Safe and Effective Gene-delivery Vectors (2014)
Optimization of a One-Step Heat-Inducible In Vivo Mini DNA Vector Production System (2014)
Separation and Purification of Linear Covalently Closed Deoxyribonucleic Acid By Q-anion Exchange Membrane Chromatography (2014)
Production of Double-stranded DNA Ministrings (2016)